| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 07/17/2003 | WO2003058021A2 Novel apoptosis-inducing dna sequences |
| 07/17/2003 | WO2003057725A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 07/17/2003 | WO2003057696A1 Deazapurines and uses thereof |
| 07/17/2003 | WO2003057252A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | WO2003057222A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/17/2003 | WO2003057219A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| 07/17/2003 | WO2003057196A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | WO2003057147A2 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/17/2003 | WO2003035838A3 Stem cells that transform to beating cardiomyocytes |
| 07/17/2003 | WO2003008410A3 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002081684A3 Antisense calpain nucleotides and uses thereof |
| 07/17/2003 | WO2002059286A3 Adenylate cyclases |
| 07/17/2003 | WO2002031134A3 Novel serine protease genes related to dppiv |
| 07/17/2003 | WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses |
| 07/17/2003 | WO2001094369A3 Heterocycle derivatives and methods of use for treating anthrax infection |
| 07/17/2003 | US20030134869 Novel therapeutic use of nicergoline |
| 07/17/2003 | US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease |
| 07/17/2003 | US20030134855 P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and ADHD |
| 07/17/2003 | US20030134850 Hydrazinyl and nitrogen oxide pyrazoles |
| 07/17/2003 | US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 07/17/2003 | US20030134836 Substituted arylamine derivatives and methods of use |
| 07/17/2003 | US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate, |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen. |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472111A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471846A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/17/2003 | CA2469480A1 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/16/2003 | EP1327630A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 07/16/2003 | EP1326972A2 Transporters and ion channels |
| 07/16/2003 | EP1326867A2 Bridged piperazine derivatives |
| 07/16/2003 | EP1326864A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 07/16/2003 | EP1326856A1 Pyridine derivatives with ikb-kinase (ikk-beta) inhibiting activity |
| 07/16/2003 | EP1326848A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 07/16/2003 | EP1326826A1 Use of amino acids for treating pain |
| 07/16/2003 | EP1326642A2 Catecholamine pharmaceutical compositions and methods |
| 07/16/2003 | EP1326619A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 07/16/2003 | EP1326606A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/16/2003 | EP1224182B1 N-substituted 1-(butyrolactone)-isoquinolines for treating nervous disorders |
| 07/16/2003 | EP1165555B1 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 07/16/2003 | CN1430620A Macrolides compound |
| 07/16/2003 | CN1430610A Substituted 1-aminoalkyl-lactams compound and their use as muscarinic receptor antagonists |
| 07/16/2003 | CN1430609A Substituted 1-aminoalkyl-lactams compound and their use as muscarinic receptor antagonists |
| 07/16/2003 | CN1430602A Ary-and heteroaryl sulfonates compounds |
| 07/16/2003 | CN1429556A Muscle strong agent and anti-inflammatory agent |
| 07/15/2003 | US6593357 Treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 07/15/2003 | US6593327 Compounds and compositions as protease inhibitors |
| 07/15/2003 | US6593313 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 07/15/2003 | US6592868 Produced by hybridoma having ATCC Accession Number HB 10916 |
| 07/15/2003 | CA2180843C Pyridine modulators of acetylcholine receptors |
| 07/10/2003 | WO2003055916A2 Adiponectin fragments and conjugates |
| 07/10/2003 | WO2003055913A2 Secreted protein |
| 07/10/2003 | WO2003055912A2 Secreted proteins |
| 07/10/2003 | WO2003055882A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 07/10/2003 | WO2003055877A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
| 07/10/2003 | WO2003055876A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 07/10/2003 | WO2003055865A1 Quinazolinone derivative |
| 07/10/2003 | WO2003055492A1 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
| 07/10/2003 | WO2003055447A2 Heterocyclic acridone inhibitors of impdh enzyme |
| 07/10/2003 | WO2002046409A3 Proteins and nucleic acids encoding same |
| 07/10/2003 | US20030130357 Inhibiting ornithine decarboxylase (involved with production of putrescine) with N(1),N(11)-diethylnorspermine |
| 07/10/2003 | US20030130352 Such as 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E for treatment of cystic fibrosis |
| 07/10/2003 | US20030130350 Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis |
| 07/10/2003 | US20030130273 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 07/10/2003 | US20030130261 Central nervous system disorders; psychological disorders; inflammatory bowel disorders |
| 07/10/2003 | US20030130260 Aryl fused azapolycyclic compounds |
| 07/10/2003 | US20030130256 Stimulant of central nervous system regeneration |
| 07/10/2003 | US20030130254 Respiratory system disorders; antihistamines; antiarthritic agents |
| 07/10/2003 | US20030130243 Hormone replacement therapy |
| 07/10/2003 | US20030130165 Method for treating neurodegenerative disorders |
| 07/10/2003 | US20030129686 Novel nucleic acid and polypeptide molecules |
| 07/10/2003 | US20030129171 Cloning mastitis gene; muscular disorders |
| 07/10/2003 | CA2471348A1 Quinazolinone derivative |
| 07/10/2003 | CA2471306A1 Secreted proteins |
| 07/10/2003 | CA2470666A1 Secreted protein |
| 07/10/2003 | CA2468619A1 Adiponectin fragments and conjugates |
| 07/09/2003 | EP1325914A1 Tetrahydroquinoline compounds |
| 07/09/2003 | EP1325117A2 Lipid metabolism enzymes |
| 07/09/2003 | EP1324994A2 Tricyclic compounds and uses thereof |
| 07/09/2003 | EP1324986A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 07/09/2003 | EP1324773A2 Use of a ppar delta activator in the treatment of diseases related to no inhibition or tnf inhibition |
| 07/09/2003 | EP1324761A2 Uridine therapy for patients with elevated purine levels |
| 07/09/2003 | EP1324760A1 Creatine ester pronutrient compounds and formulations |
| 07/09/2003 | CN1429222A 激酶抑制剂 Kinase inhibitors |
| 07/09/2003 | CN1429113A Nutritional preparation comprising ribose and folic acid and medical use thereof |
| 07/08/2003 | US6589978 Therapy for nervous system disorders |
| 07/08/2003 | US6589748 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 07/08/2003 | US6589503 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| 07/03/2003 | WO2003054012A2 Leptin proteins |
| 07/03/2003 | WO2003053961A1 Benzothiazoles |
| 07/03/2003 | WO2003053955A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 07/03/2003 | WO2003053407A1 Liposomal delivery of vitamin e based compounds |
| 07/03/2003 | WO2003053364A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| 07/03/2003 | WO2003053354A2 Fused cyclic modulators of nuclear hormone receptor function |
| 07/03/2003 | WO2003053346A2 Systems and methods for treating patients with processed lipoaspirate cells |
| 07/03/2003 | WO2003053336A2 Methods for the treatment of peripheral neural and vascular ailments |